Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
NCT ID: NCT01219907
Last Updated: 2013-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase I trial is studying the side effects and best dose of ex vivo-expanded HER2-specific T cells when given together with cyclophosphamide after vaccine therapy in treating patients with HER2-positive stage IV breast cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
NCT01022138
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT07112053
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT05378464
Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer
NCT00399529
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
NCT02957968
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To evaluate the feasibility of expanding HER-2-specific effector T cells (TE) ex vivo from CD62L+ TCM and CD62L- TEM from patients immunized with a HER-2 peptide vaccine.
II. To evaluate the safety of infusing autologous ex vivo expanded HER-2-specific T cells into patients with advanced HER-2+ breast cancer.
SECONDARY OBJECTIVES:
I. To evaluate the persistence, function, and phenotype of adoptively transferred HER-2-specific TE cells derived from TCM or TEM precursors.
II. To investigate the potential anti-tumor effects of therapy with ex vivo expanded HER-2-specific T cells in patients with advanced HER-2+ breast cancer.
OUTLINE : This is a dose-escalation study of ex vivo-expanded HER2-specific T cells.
VACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.
CHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.
IMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20.
After completion of study treatment, patients are followed up on days 28, 35, 49, 63 and then monthly thereafter for 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
VACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.
CHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.
IMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20.
HER-2/neu peptide vaccine
Given intradermally
cyclophosphamide
Given IV
ex vivo-expanded HER2-specific T cells
Given IV
laboratory biomarker analysis
Correlative studies
flow cytometry
Correlative studies
immunoenzyme technique
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HER-2/neu peptide vaccine
Given intradermally
cyclophosphamide
Given IV
ex vivo-expanded HER2-specific T cells
Given IV
laboratory biomarker analysis
Correlative studies
flow cytometry
Correlative studies
immunoenzyme technique
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must be \> 18 years old
* Extra skeletal disease that can be accurately measured in at least one dimension as \>= 20 mm with conventional CT techniques or \>= 10 mm with spiral CT scan
* Skeletal or bone-only disease that is measurable by FDG PET imaging will also be allowed
* Patients can be receiving trastuzumab and/or hormonal therapy and/or bisphosphonates
* HER2 overexpression in the primary tumor or metastasis by IHC of 2+ or 3+, or documented gene amplification by FISH analysis; if over expression is 2+ by IHC, patients must have HER2 gene amplification documented by FISH
* Performance Status Score (ECOG/Zubrod Scale) must be =\< 2
* Patients must be off all immunosuppressive treatments such as chemotherapy or systemic steroid therapy a minimum of 3 weeks prior to initiation of study (i.e. first vaccination)
* Patients on trastuzumab must have a baseline LVEF measured by MUGA or echocardiogram \>= the lower limit of normal for the facility within 3 months of enrollment to study
* Subjects must be HLA-A2 (HLA A\*0201) positive
* ANC \>= 1000/mm\^3
* Hgb \>= 10 mg/dl
* Platelet count \>= 75,000/mm\^3
* Men and women of reproductive ability must agree to use contraceptives during the entire study period
Exclusion Criteria
* Serum bilirubin \> 2.5 times the upper limit of normal
* Contraindication to receiving GM-CSF based vaccine products
* New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, or unstable angina
* History of disorders associated with immunosuppression such as HIV
* Pregnant or breast-feeding women
* ANC \< 1000/mm\^3
* Hgb \< 10 mg/dl
* Platelet count \< 75,000/mm\^3
* Active brain metastasis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Washington
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lupe Salazar
Role: PRINCIPAL_INVESTIGATOR
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2010-01792
Identifier Type: -
Identifier Source: secondary_id
7266
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.